Lilly and OSI Pharmaceuticals Announce Licensing Agreement
LIlly has announced they are licensing the compound PSN010 from OSI Pharmaceutical’s subsidiary Prosidion for an upfront payment of $25 million and an additional $360 million in development milestones.
PharmaLive: Lilly and OSI Pharmaceuticals Announce Licensing Agreement :
This is an early stage compound (phase I) for diabetes type 2 and it activates oral glucokinase.
Again, I think it is interesting to see some companies going the mergers and acquisitions (M&A) route while others are making deals for compounds. I’ve stated before I personally think the deal making is the better approach since this doesn’t kill the innovations of the small company. I look at mergers as killing the goose to get the golden eggs.
Other Resources
PSN010 - Yahoo! Search Results
Technorati Tags: Eli Lilly, OSI Pharmaceuticals, Prosidion, PSN010
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
